Abbott Laboratories (ABT)
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Global Growth Composite Portfolio ret...
You can probably hold onto these winners beyond 2030.
Abbott Laboratories (NYSE: ABT) reported strong third-quarter results Wednesday and looks able to generate double-digit earnings growth going ahead, even without considering testing revenue, a...
The COVID-19 pandemic will likely get worse before it gets better. These two stocks could be safe havens for investors.
Abbott Laboratories (ABT) CEO Robert Ford on Q3 2020 Results - Earnings Call Transcript
Revenue and earnings beats were only part of the story.
Abbott Laboratories (NYSE: ABT) published its earnings report for the fiscal third quarter on Wednesday. The company said that its earnings in Q3 came in stronger than what analysts had expect...
In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
Abbott (ABT) delivered earnings and revenue surprises of 8.89% and 4.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Abbott Laboratories posted Q3 earnings and revenue that exceeded Wall Street expectations, as did its earnings guidance for the year. The post Abbott Laboratories Earnings, Outlook Top Expecta...
Abbott Laboratories posted stronger-than-expected third-quarter earnings Wednesday and offered upbeat guidance for the full year, despite the uncertainty created by the pandemic. The company p...
Shares of Abbott Laboratories (NYSE:ABT) rose 1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 16.67% year over year to $0.98, which be...
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
ABBOTT PARK, Ill., Oct. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2020. Third-quarter worldwide sales of $8.9 billion ...
Logitech, Philip Morris, Verizon, Abbott Labs and iRobot were our top stock trades for Wednesday. That said, here's a look at the charts.
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ABBOTT PARK, Ill., Oct. 19, 2020 /PRNewswire/ -- Researchers at the University of Illinois, Urbana-Champaign, Abbott (NYSE: ABT), and the U.S. Air Force Research Lab announced today the result...
These stocks are all up more than 20% this year.
Solid dividends plus strong growth prospects add up to great stocks to buy.
These companies have benefited significantly from the COVID-19 pandemic already, and it looks like they have much more room to grow.
Abbott (ABT) is expected to register strong sales in the Adult Nutrition category, banking on growing global demand for its nutrition brand Ensure.
Investment in low-beats stocks with a favorable Zacks Rank and positive Earnings ESP will be a sound strategy to enhance one's portfolio.
In the latest trading session, Abbott (ABT) closed at $107.75, marking a -0.57% move from the previous day.
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Our indicative theme of Covid-19 Testing Stocks, which includes medical devices and diagnostic companies that are involved in Covid-19 testing - is up by about 69% year-to-date, significantly ...
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shares of Abbott Laboratories were down 1.6% in trading on Tuesday, the day after the company said it had received emergency authorization from the Food and Drug Administration for a new COVID...
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
A market downturn can't stop these two top healthcare stocks.
These stocks could share big news this month, loosening the grip of the coronavirus on our lives.
These two companies are both banking on the success of their coronavirus products.
Their coronavirus programs are only part of the attraction for these stocks.
This healthcare company will benefit from coronavirus-related demand now -- and the rest of its solid business will benefit later.
If you had asked investors in the middle of March this year if they thought the U.S.
These stocks are well-positioned whether turbulent times come or not.
Abbott Laboratories Says Its Rapid Coronavirus Test Correctly Identifies Positive Cases 95% of the Time
The interim clinical data indicates that ID NOW flags infected patients in nearly every instance.
The rapid-response, point-of-care tests should trim the long lines seen at some of the country's testing sites.
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
These three companies are stable, in demand, and capably led.
Abbott (ABT) closed the most recent trading day at $108.56, moving +1.93% from the previous trading session.
Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into...
ABT is securing more orders for millions of its rapid covid-19 testing kits.
These two companies are making headway against the pandemic in key areas.
With an increasing share of the coronavirus diagnostic testing market, Abbott is positioned for substantial growth.
This new test is cheap, fast, reliable, and digitally integrated.